Autoimmune polyendocrine syndrome type 1 and NALP5, parathyroid autoantigen

Alimohammadi, M; Bjorklund, P; Hallgren, A; Pontynen, N; Szinnai, G; Shikama, N; Keller, MP; Ekwall, O; Kinkel, SA; Husebye, ES; Gustafsson, J; Rorsman, F; Peltonen, L; Betterle, C; Perheentupa, J; Akerstrom, G; Westin, G; Scott, HS; Hollander, GA; Kampe, O

Author(s): Alimohammadi, M; Bjorklund, P; Hallgren, A; Pontynen, N; Szinnai, G; Shikama, N; Keller, MP; Ekwall, O; Kinkel, SA; Husebye, ES; Gustafsson, J; Rorsman, F; Peltonen, L; Betterle, C; Perheentupa, J; Akerstrom, G; Westin, G; Scott, HS; Hollander, GA; Kampe, O;
Details: Publication Year 2008-03-06,Volume 358,Issue #10,Page 1018-1028
Journal Title: NEW ENGLAND JOURNAL OF MEDICINE
Publication Type: Journal Article
Abstract: Background: Autoimmune polyendocrine syndrome type 1 (APS-1) is a multiorgan autoimmune disorder caused by mutations in AIRE, the autoimmune regulator gene. Though recent studies concerning AIRE deficiency have begun to elucidate the molecular pathogenesis of organ-specific autoimmunity in patients with APS-1, the autoantigen responsible for hypoparathyroidism, a hallmark of APS-1 and its most common autoimmune endocrinopathy, has not yet been identified. Methods: We performed immunoscreening of a human parathyroid complementary DNA library, using serum samples from patients with APS-1 and hypoparathyroidism, to identify patients with reactivity to the NACHT leucine-rich-repeat protein 5 (NALP5). Subsequently, serum samples from 87 patients with APS-1 and 293 controls, including patients with other autoimmune disorders, were used to determine the frequency and specificity of autoantibodies against NALP5. In addition, the expression of NALP5 was investigated in various tissues. Results: NALP5-specific autoantibodies were detected in 49% of the patients with APS-1 and hypoparathyroidism but were absent in all patients with APS-1 but without hypoparathyroidism, in all patients with other autoimmune endocrine disorders, and in all healthy controls. NALP5 was predominantly expressed in the cytoplasm of parathyroid chief cells. Conclusions: NALP5 appears to be a tissue-specific autoantigen involved in hypoparathyroidism in patients with APS-1. Autoantibodies against NALP5 appear to be highly specific and may be diagnostic for this prominent component of APS-1.
Publisher: MASSACHUSETTS MEDICAL SOC
Keywords: CANDIDIASIS-ECTODERMAL DYSTROPHY; CALCIUM-SENSING RECEPTOR; REGULATORY T-CELLS; SYNDROME TYPE-I; ADRENAL INSUFFICIENCY; EMBRYONIC-DEVELOPMENT; ACID DECARBOXYLASE; DISEASE; MICE; AUTOANTIBODIES
Publisher's Version: https://doi.org/10.1056/NEJMoa0706487
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2008-03-06 12:00:00